Portal de investigação
Management of Coronavirus Disease 2019 Patients With Lung Cancer: Experience From a Thoracic Oncology Center
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Coelho, DB
- Santos, V
- Araújo, D
- Magalhaes, A
- Queiroga, H
- Cruz-Martins, N
Unidades de investigação
Abstract
Background Cancer patients appear to be at a higher risk of complications from coronavirus disease 2019 (COVID-19). Specific data related to lung cancer (LC) patient management, active treatment, and/or recent diagnosis are still very limited. Here, we aimed to investigate the clinical presentation, baseline features, and clinical outcomes of LC patients with COVID-19. Methods A retrospective case study was performed at Centro Hospitalar Universitario de Sao Joao, a tertiary hospital in the North of Portugal. Data from LC patients diagnosed with COVID-19 were collected during the first 10 months of the COVID-19 pandemic (March 2020-January 2021). Results Twenty-eight patients with active LC were diagnosed with COVID-19, being adenocarcinoma the most common histological type present (n = 13, 46.4%). Sixteen patients had metastatic stage IV LC (61.5%). Twenty-five patients (89.3%) had relevant comorbidities including hypertension (39.3%) and chronic obstructive pulmonary disease (32.1%). For patients undergoing antineoplastic treatment, the median time from the last chemotherapy administration to COVID-19 diagnosis was of 16 days (interquartile range = 13-41 days). Half of patients were previously on corticosteroid therapy. Twenty patients (71.4%) needed hospitalization, 18 received oxygen therapy (64.3%), 3 (10.7%) of them received high-flow nasal cannula with good tolerability, and 1 (3.6%) needed non-invasive ventilation. Hydroxychloroquine and antibiotics were given to 4 (14.3%) and 12 (42.9%) patients, respectively. Seven patients (25%) died at a median time of 5 days following COVID-19 diagnosis. Conclusion This is one of the first studies reporting the adverse outcomes associated with COVID-19 in LC patients at same time that adds evidence regarding the need to create protocols and guidelines to reduce the infection risk in such patients.
Dados da publicação
- ISSN/ISSNe:
- 2296-889X, 2296-889X
- Tipo:
- Article
- Páginas:
- -
- Link para outro recurso:
- www.scopus.com
Frontiers in Molecular Biosciences Frontiers Media S.A.
Citações Recebidas na Scopus: 1
Documentos
- Não há documentos
Filiações
Keywords
- COVID-19; lung cancer; infection; thoracic oncology; clinical management
Financiamento
Proyectos asociados
Fibrosing ILD Biomarkers That Rule Acceleration (FIBRALUNG) -NCT05635032
Investigador Principal: Hélder Novais e Bastos
Estudo Observacional Académico (FIBRALUNG) . FCT . 2021
Doença do Refluxo Gastro-esofágico e Doença Pulmonar
Investigador Principal: Venceslau José Coelho Pinto Hespanhol
Estudo Clínico Académico (Refluxo Gastro-esofágic) . 2020
A importância do diagnóstico na Fibrose Pulmonar Idiopática
Investigador Principal: Venceslau José Coelho Pinto Hespanhol
Estudo Clínico Académico (FPI) . 2020
Chronic Bronchopulmonary aspergillosis patients with underlying chronic obstructive pulmonary disease: providing grounds for biomarkers search through clinical phenotyping
Investigador Principal: Hélder Novais e Bastos
Estudo Clínico Académico . 2020
Non-invasive assessment of Benign Tracheal Stenosis.
Investigador Principal: Hélder Novais e Bastos
Estudo Clínico Académico . 2020
Imunoterapia no cancro do pulmão: PD-L1, biomarcador preditivo?
Investigador Principal: Venceslau José Coelho Pinto Hespanhol
Estudo Clínico Académico . 2020
Citar a publicação
Coelho DB,Santos V,Araújo D,Bastos H,Magalhaes A,Hespanhol V,Queiroga H,Cruz N,Fernandes M. Management of Coronavirus Disease 2019 Patients With Lung Cancer: Experience From a Thoracic Oncology Center. Front. Mol. Biosci. 2021. 8. 639676. IF:6,113. (1).
